Not a good buy right now for an impatient trader: the stock is in a clear downtrend (bearish MAs, MACD deteriorating) with no near-term catalyst in the news flow.
Current price (~9.73 pre-market) is sitting right on key support (S1 ~9.56); downside risk to the next support (S2 ~8.24) is meaningful if support breaks.
Options positioning (low put/call OI ratio) looks bullish, but ultra-high implied volatility and zero reported daily option volume make the sentiment signal less reliable.
Analysts are very bullish ($35 targets), but the fundamental value case is longer-dated (initial CR-001 data not expected until Q1 2027), which doesn’t align well with an “act now” impatience profile.
Momentum: MACD histogram is negative (-0.309) and negatively expanding, suggesting bearish momentum is strengthening.
RSI: RSI_6 at ~21.1 indicates very weak/washed-out conditions (oversold-type behavior), but oversold can persist in downtrends.
Levels: Support S1 ~9.56 (very close to current), then S2 ~8.24. Resistance at Pivot ~11.70, then R1 ~13.85.
Pattern-based short-horizon odds: model implies modest 1-day/1-week upside but a negative 1-month skew (-5.15%), consistent with the broader downtrend.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Open interest: Calls 6,359 vs puts 2,614; put/call OI ratio 0.41 = bullish skew (more call positioning than puts).
Volume: reported options volume is 0 today, so near-term sentiment from flow is not confirmable from this snapshot.
Implied volatility: extremely elevated (30D IV ~498%), implying the market is pricing large potential moves; this often reflects event/speculation risk rather than steady directional conviction.
Takeaway: positioning looks optimistic, but the combination of extreme IV + no volume data today reduces confidence in using options as a “buy now” confirmation.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
Wall Street initiation wave: two recent initiations (Guggenheim + Piper Sandler) with Buy/Overweight and $35 targets can support sentiment/awareness.
Pipeline narrative: CR-001 positioned as PD-1xVEGF bsAb with potential subQ angle; additional ADC pipeline optionality could attract speculative interest.
If peer read-through improves (e.g., positive momentum around Summit/ivonescimab thesis referenced by Guggenheim), CBIO could get sympathy valuation support even before its own data.
Neutral/Negative Catalysts
Extremely high implied volatility suggests the market expects large swings; without a defined catalyst, this can work against “buy now” timing.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (still pre-revenue), no sign of commercial ramp.
Profitability: Net income -$24.6M (still deeply loss-making); EPS -1.49.
Trend read: financial profile remains development-stage with ongoing burn; the investment case is primarily pipeline/clinical optionality rather than improving operating fundamentals in the latest quarter.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: two initiations in January 2026 with strongly bullish stances.
[2026-01-21] Guggenheim: Buy, PT $35; highlights CR-001 data timing (Q1 2027) and ADC pipeline as independent value + synergy.
Wall Street cons (implied by their own notes): long wait to meaningful data (12–15 months+), execution risk typical of early oncology programs, and valuation support may be sentiment-driven until clinical readouts.
Politicians / influential figures: no recent congress trading data available in the last 90 days; no politician activity identified from the provided data.
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 28.2 USD with a low forecast of 22 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBIO is 28.2 USD with a low forecast of 22 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.410
Low
22
Averages
28.2
High
35
Current: 9.410
Low
22
Averages
28.2
High
35
Piper Sandler
Overweight
initiated
$35
AI Analysis
2026-01-28
Reason
Piper Sandler
Price Target
$35
AI Analysis
2026-01-28
initiated
Overweight
Reason
Piper Sandler initiated coverage of Crescent Biopharma with an Overweight rating and $35 price target. The firm notes the company's lead asset CR-001 is a PD-1xVEGF bsAb designed to match ivonescimab's cooperativity with potential for subQ administration. A Phase 1/2 is initiating in Q1 2026 to evaluate the asset in several solid tumors. Piper models three indications based on demonstrated efficacy of PD-1xVEGF bsAb in these indications, and cumulatively models about $1.4B in risk-adjusted revenues by 2036. Moreover, the company has a pipeline of ADCs and is at the forefront of this next wave of oncology development combining PD1xVEGF with ADCs.
Guggenheim
Brad Canino
Buy
initiated
$35
2026-01-21
Reason
Guggenheim
Brad Canino
Price Target
$35
2026-01-21
initiated
Buy
Reason
Guggenheim analyst Brad Canino initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $35 price target. Crescent is 12-15 months from initial CR-001 data due in Q1 of 2027 that will include first-line lung patients to provide a clear comparable to Summit Therapeutics' (SMMT) ivonescimab and the company unveiled a proprietary ADC pipeline against two clinically validated targets that can generate independent value with monotherapy activity and be synergistic with CR-001 in earlier solid tumor treatment settings, the analyst tells investors. If the firm's Summit ivonescimab thesis plays out successfully in 2026, "like we think it will," the firm sees Crescent being set up to be "awarded significant value both from what the company is replicating and what the company is pioneering," the analyst added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CBIO
